
    
      In the Phase I portion, both 3 hour and 24 hour infusions of obatoclax with carboplatin and
      etoposide every 3 weeks will be evaluated at different doses. In the Phase II portion, 3 hour
      infusions of obatoclax with or without carboplatin and etoposide every three weeks will be
      evaluated for response rates.
    
  